Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial

被引：14

作者：

Extra, J. M. ^{[1
]}

Cognetti, F. ^{[2
]}

Maraninch, D. ^{[3
]}

Snyder, R. ^{[4
]}

Mauriac, L. ^{[5
]}

Tubiana-Hulin, M. ^{[6
]}

Chan, S. ^{[7
]}

Grimes, D. ^{[8
]}

Anton, A. ^{[9
]}

Marty, M.

机构：

[1] Inst Curie, Serv Chimiotherapie, Paris, France

[2] Regina Elena Inst Canc Res, I-00161 Rome, Italy

[3] Inst J Paoli I Calmettes, Dept Med, F-13009 Marseille, France

[4] St Vincents Hosp, Dept Oncol, Fitzroy, Vic 3065, Australia

[5] Inst Bergonie, MEC Med Ctr, Bordeaux, France

[6] Ctr Rene Huguenin, Med Oncol Serv, St Cloud, France

[7] City Hosp Nottingham, Dept Clin Oncol, Nottingham, England

[8] Wesley Med Ctr, Clin Oncol, Auchenflour, Australia

[9] Hosp Miguel Servet, Dept Oncol, Zaragoza, Spain

来源：

EJC SUPPLEMENTS | 2004年 / 2卷 / 03期

关键词：

D O I：

10.1016/S1359-6349(04)90842-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

239

引用

页码：125 / 126

页数：2